NorthWest Biotherapeutics Inc (NWBO)

[Rkmatters]

It was not a progression event. His scan did not get worse, which is necessary to see to qualify as MacDonald progression.

See Figure 1 of this GBM study as it is how progression is determined.

MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients.

http://jco.ascopubs.org/content/26/13/2192.full.pdf


And there was no confirmed TUMOR to start so obviously he would not be a measurable disease response patient. But you like to pretend he had TUMOR to start with in order to construe in the context of Avastin which not the appropriate study to use as they needed to alert how slides should be analyzed. Try sticking to using GBM studies that only use Radiation, TMZ, and surgery. That was all Brad had beyond DCVax-L prior to that first scan. You giving me a progression tree of Avastin, TMZ and RT instead of using Brandes study that I posted is telling.